Brief: Immunocore Expects To Report Prelim Unaudited Net Product Revenue From Sales Of Kimmtrak Of About $66 Mln For Q4

Immunocore Holdings

29/01/2024 22:26

Jan 29 (Reuters) - Immunocore Holdings PLC  IMCR.O :
    * IMMUNOCORE HOLDINGS -  EXPECTS TO REPORT PRELIMINARY
UNAUDITED
NET PRODUCT REVENUE ARISING FROM SALES OF KIMMTRAK OF ABOUT $66
MILLION FOR Q4 2023
    * IMMUNOCORE HOLDINGS PLC- PRELIMINARY UNAUDITED CASH AND
CASH
EQUIVALENTS AT DECEMBER 31, 2023 WAS ABOUT $443 MILLION
    * IMMUNOCORE HOLDINGS-  EXPECTS TO REPORT PRELIMINARY
UNAUDITED
NET PRODUCT REVENUE ARISING FROM SALES OF KIMMTRAK OF ABOUT $235
MILLION FOR FULL YEAR 2023
    * IMMUNOCORE SEES INCREASE IN Q4 RESEARCH AND DEVELOPMENT
EXPENSES
AND SG&A EXPENSES VERSUS Q3

Source text for Eikon:  ID:n0001140361-24-004321 
Further company coverage:  IMCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))